Announced
Financials
Tags
Friendly
Acquisition
Private
Cross Border
Minority
China
Private Equity
biotechnology company
Biotechnology
Pending
Single Bidder
Synopsis
Temasek, a Singaporean state-owned conglomerate, and HighLight Capital, a Chinese investment firm, agreed to acquire a 24% stake in a Shanghai unit of VIVA Biotech, a highly specialized contract research organization, for $149m. "It is our great honor to introduce renowned strategic investors who will furnish and enhance our key strategic decisions and long-term investment and financing plans. Despite the recession in investment and financing, we are able to secure investment from established institutions, by virtue of our pioneering spirit and continuous innovation in the past. This demonstrates the market's recognition of our business foundation and confidence in our development prospect. Furthermore, the commitment to our goal of A-shares listing and the valuation premium from A-shares compared to HK stock market will facilitate the financing needs for our future development. in addition, our plan to increase executive share ownership and provide Employee Stock Ownership Plan to the core team members will revitalize Viva and open up new opportunities for our long-term growth," Cheney Mao, Viva Biotech Chairman and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.